<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02538354</url>
  </required_header>
  <id_info>
    <org_study_id>METc 2014/291</org_study_id>
    <secondary_id>Protocol ID</secondary_id>
    <nct_id>NCT02538354</nct_id>
  </id_info>
  <brief_title>The Effect of Riboflavin in Crohn's Disease</brief_title>
  <acronym>RISE-UP</acronym>
  <official_title>The Effect of Riboflavin Supplementation on Faecalibacterium Prausnitzii in Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate if suppelementation of the diet with riboflavin in Crohn's disease
      patients will result in an increase in the amount of F. prausnitzii.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale Recent studies show that in patients with Inflammatory Bowel Disease (IBD) a
      dysbiosis exists in the composition of the intestinal microbiota. In particular, the
      potentially pathogenic bacterium Escherichia coli (E. coli) is often more abundant in the
      bowel of IBD patients, and the anaerobic commensal Faecalibacterium prausnitzii (F.
      prausnitzii) is often reduced. This last mentioned bacteria is known to be abundant in the
      intestine of healthy individuals. It is known to produce butyrate, which stimulates the
      intestinal epithelium, and to secrete anti-inflammatory substances.

      Riboflavin - also known as vitamin B2 - is required for a wide variety of cellular processes
      and has an important role in maintaining health in humans. In a pilot intervention with
      healthy volunteers it is shown that a riboflavin supplement increases the number of F.
      prausnitzii and results in a higher production of butyrate. In Crohn's disease patients, it
      is known that the amount of F. prausnitzii in the intestine is generally low. Furthermore, it
      is known that there is an association between the number of F. prausnitzii bacteria and the
      length of disease in remission.

      This study will evaluate if supplementation of the diet with riboflavin in Crohn's disease
      patients will result in a similar increase in the amount of F. prausnitzii as in healthy
      volunteers. In this patient group, an increase in the number of F. prausnitzii bacteria in
      the bowel may result in a more favourable disease course. This will be assessed with faeces
      calprotectin and two questionnaires. Additionally the investigators will assess if there is
      any modulation by riboflavin on the other intestinal bacteria, short chain fatty acids
      (SCFAs) (such as butyrate), and the pH of the faeces. Finally, the effect of the riboflavin
      on the permeability of the gut will be evaluated with a Chroom-EDTA test, and a number of
      different biomarkers of permeability.

      Hypothesis The hypothesis is that in Crohn's disease patients, supplementation of the diet
      with riboflavin results in an increase in the amount of F. prausnitzii, changes in microbial
      composition, increased fatty acid production, an increase in pH and a reduction of intestinal
      permeability. These changes might result in a more favourable disease course with less
      exacerbations.

      Study design Prospective clinical study.

      Study population and sample size In total 84 Crohn's disease patients will be included in
      this study, divided into two groups. Group 1 (n=42) will consist of patients with disease in
      remission (quiescent disease); group 2 (n=42) will consist of patients with active disease.
      In this study an adaptive design will be used. First 12 patients in the disease in remission
      group will be analysed. The methods of analysis and safety aspects will be taken into
      account.

      Intervention Supplementation of the normal diet with 1 capsule of 100 mg riboflavin (vitamin
      B2) during three weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>F. Prausnitzii (FISH Analysis).</measure>
    <time_frame>Different time points up to 6 weeks from start study: Day0, Day7, Day28</time_frame>
    <description>The faeces is collected at different time points before and after riboflavin supplementation. To investigate the effect of a riboflavin supplement on the number of F. prausnitzii bacteria in the faeces of active and quiescent Crohn's disease patients.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>Riboflavin supplementation in quiescent disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 (n=42) will consist of patients with disease in remission (quiescent disease).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Riboflavin supplementation in active disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 (n=42) will consist of patients with active disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Riboflavin supplementation</intervention_name>
    <description>Supplementation of the normal diet with 1 capsule of 100 mg riboflavin (vitamin B2) during three weeks</description>
    <arm_group_label>Riboflavin supplementation in active disease</arm_group_label>
    <arm_group_label>Riboflavin supplementation in quiescent disease</arm_group_label>
    <other_name>vitamin B2 supplementation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Crohn's disease patients

          -  Age 18-65 years

          -  Concomitant medication for Crohn's disease is allowed in all groups

        Exclusion Criteria:

          -  Swallowing disorders

          -  Pregnancy and lactation

          -  Use of antibiotic drugs, probiotics (i.e.Yakult, Vifit, Activia etc) or specific
             prebiotic supplements in the 3 weeks prior to the riboflavin intervention

          -  Use of Methotrexate drugs

          -  Colonoscopy and colon cleansing in last 3 months

          -  Use of a vitamin B2 supplement, or multivitamin complexes containing vitamin B (i.e.
             vitamin B-complex) in the 3 weeks prior to the riboflavin intervention

          -  Severe Crohn's disease (HBI &gt; 12)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008 Feb;134(2):577-94. doi: 10.1053/j.gastro.2007.11.059. Review.</citation>
    <PMID>18242222</PMID>
  </reference>
  <reference>
    <citation>Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16731-6. doi: 10.1073/pnas.0804812105. Epub 2008 Oct 20.</citation>
    <PMID>18936492</PMID>
  </reference>
  <reference>
    <citation>Fujimoto T, Imaeda H, Takahashi K, Kasumi E, Bamba S, Fujiyama Y, Andoh A. Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn's disease. J Gastroenterol Hepatol. 2013 Apr;28(4):613-9. doi: 10.1111/jgh.12073.</citation>
    <PMID>23216550</PMID>
  </reference>
  <reference>
    <citation>Willing B, Halfvarson J, Dicksved J, Rosenquist M, Järnerot G, Engstrand L, Tysk C, Jansson JK. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. Inflamm Bowel Dis. 2009 May;15(5):653-60. doi: 10.1002/ibd.20783.</citation>
    <PMID>19023901</PMID>
  </reference>
  <reference>
    <citation>Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, Cosnes J, Corthier G, Marteau P, Doré J. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis. 2009 Aug;15(8):1183-9. doi: 10.1002/ibd.20903.</citation>
    <PMID>19235886</PMID>
  </reference>
  <reference>
    <citation>Miquel S, Martín R, Rossi O, Bermúdez-Humarán LG, Chatel JM, Sokol H, Thomas M, Wells JM, Langella P. Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol. 2013 Jun;16(3):255-61. doi: 10.1016/j.mib.2013.06.003. Epub 2013 Jul 3. Review.</citation>
    <PMID>23831042</PMID>
  </reference>
  <reference>
    <citation>Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett. 2009 May;294(1):1-8. doi: 10.1111/j.1574-6968.2009.01514.x. Epub 2009 Feb 13. Review.</citation>
    <PMID>19222573</PMID>
  </reference>
  <reference>
    <citation>Khan MT, Duncan SH, Stams AJ, van Dijl JM, Flint HJ, Harmsen HJ. The gut anaerobe Faecalibacterium prausnitzii uses an extracellular electron shuttle to grow at oxic-anoxic interphases. ISME J. 2012 Aug;6(8):1578-85. doi: 10.1038/ismej.2012.5. Epub 2012 Feb 23.</citation>
    <PMID>22357539</PMID>
  </reference>
  <reference>
    <citation>Swidsinski A, Loening-Baucke V, Vaneechoutte M, Doerffel Y. Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm Bowel Dis. 2008 Feb;14(2):147-61.</citation>
    <PMID>18050295</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 20, 2015</study_first_submitted>
  <study_first_submitted_qc>August 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2015</study_first_posted>
  <results_first_submitted>March 1, 2020</results_first_submitted>
  <results_first_submitted_qc>March 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 3, 2020</results_first_posted>
  <last_update_submitted>March 22, 2020</last_update_submitted>
  <last_update_submitted_qc>March 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Prof. dr. G. Dijkstra</investigator_full_name>
    <investigator_title>Prof. dr. G. Dijkstra</investigator_title>
  </responsible_party>
  <keyword>Riboflavin (vitamin B2)</keyword>
  <keyword>Faecalibacterium prausnitzii</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 10, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT02538354/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Riboflavin Supplementation in Quiescent Disease</title>
          <description>Group 1 (n=42) will consist of patients with disease in remission (quiescent disease).
Riboflavin supplementation: Supplementation of the normal diet with 1 capsule of 100 mg riboflavin (vitamin B2) during three weeks</description>
        </group>
        <group group_id="P2">
          <title>Riboflavin Supplementation in Active Disease</title>
          <description>Group 2 (n=42) will consist of patients with active disease.
Riboflavin supplementation: Supplementation of the normal diet with 1 capsule of 100 mg riboflavin (vitamin B2) during three weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Riboflavin Supplementation in Quiescent Disease</title>
          <description>Group 1 (n=42) will consist of patients with disease in remission (quiescent disease).
Riboflavin supplementation: Supplementation of the normal diet with 1 capsule of 100 mg riboflavin (vitamin B2) during three weeks</description>
        </group>
        <group group_id="B2">
          <title>Riboflavin Supplementation in Active Disease</title>
          <description>Group 2 (n=42) will consist of patients with active disease.
Riboflavin supplementation: Supplementation of the normal diet with 1 capsule of 100 mg riboflavin (vitamin B2) during three weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.2" spread="11.6"/>
                    <measurement group_id="B2" value="38.8" spread="13.6"/>
                    <measurement group_id="B3" value="41.9" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>F. Prausnitzii (FISH Analysis).</title>
        <description>The faeces is collected at different time points before and after riboflavin supplementation. To investigate the effect of a riboflavin supplement on the number of F. prausnitzii bacteria in the faeces of active and quiescent Crohn's disease patients.</description>
        <time_frame>Different time points up to 6 weeks from start study: Day0, Day7, Day28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Riboflavin Supplementation in Quiescent Disease</title>
            <description>Group 1 (n=42) will consist of patients with disease in remission (quiescent disease).
Riboflavin supplementation: Supplementation of the normal diet with 1 capsule of 100 mg riboflavin (vitamin B2) during three weeks</description>
          </group>
          <group group_id="O2">
            <title>Riboflavin Supplementation in Active Disease</title>
            <description>Group 2 (n=42) will consist of patients with active disease.
Riboflavin supplementation: Supplementation of the normal diet with 1 capsule of 100 mg riboflavin (vitamin B2) during three weeks</description>
          </group>
        </group_list>
        <measure>
          <title>F. Prausnitzii (FISH Analysis).</title>
          <description>The faeces is collected at different time points before and after riboflavin supplementation. To investigate the effect of a riboflavin supplement on the number of F. prausnitzii bacteria in the faeces of active and quiescent Crohn's disease patients.</description>
          <units>Relative FISH counts from total bacteria</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T0 (Mean of Day 0 and Day 7 combined)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.53" lower_limit="0.00" upper_limit="12.77"/>
                    <measurement group_id="O2" value="5.07" lower_limit="0.00" upper_limit="14.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3 (Day 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.19" lower_limit="0.00" upper_limit="13.10"/>
                    <measurement group_id="O2" value="5.46" lower_limit="0.00" upper_limit="11.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <desc>No adverse events observed in this study</desc>
      <group_list>
        <group group_id="E1">
          <title>Riboflavin Supplementation in Quiescent Disease</title>
          <description>Group 1 (n=42) will consist of patients with disease in remission (quiescent disease).
Riboflavin supplementation: Supplementation of the normal diet with 1 capsule of 100 mg riboflavin (vitamin B2) during three weeks</description>
        </group>
        <group group_id="E2">
          <title>Riboflavin Supplementation in Active Disease</title>
          <description>Group 2 (n=42) will consist of patients with active disease.
Riboflavin supplementation: Supplementation of the normal diet with 1 capsule of 100 mg riboflavin (vitamin B2) during three weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>dr. J.Z.H. von Martels</name_or_title>
      <organization>Universy Medical Center Groningen</organization>
      <phone>0031503616161</phone>
      <email>j.z.h.von.martels@umcg.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

